JNJ stock $218.55 (NYSE) 16 Jan 2026: Q4 earnings Jan 21, watch margins
JNJ stock trades at $218.55 on the NYSE as of 16 Jan 2026, with investors focused on the Q4 earnings report scheduled for 21 Jan 2026. Expectations center on margin trends in Innovative Medicine and MedTech after Kenvue separated. Key live metrics: P/E 21.19, EPS 10.36, volume 11,858,800. This earnings spotlight uses Meyka AI as an AI-powered market analysis platform to connect reported metrics, analyst posture and short-term trading signals ahead of the release.
JNJ stock: earnings calendar and what to expect
Johnson & Johnson (JNJ) will report Q4 results on 21 Jan 2026 (pre-market US time). The market will focus on revenue growth, margins in Pharmaceuticals and MedTech, and any guidance update. Analysts show a consensus tilt to Buy with 19 Buys, 7 Holds, 1 Sell. Volume average is 8,498,991 shares and today’s traded volume is 11,858,800, suggesting above-normal attention into earnings.
JNJ stock: near-term catalysts and downside risks
Catalysts include new drug launches and device procedure volume trends; key risk is weaker-than-expected pricing or margin pressure in MedTech. Recent financial growth shows revenue +4.30% (FY 2024) but EPS contraction year-over-year. Investors should watch guidance tone and any comment on R&D or supply-chain costs that could shift short-term earnings multiples.
JNJ stock: financials and valuation snapshot
Johnson & Johnson posts Market Cap $529.03B in the United States market and a trailing PE of 21.19 with EPS 10.36. Key ratios: ROE 32.69%, free cash flow yield 3.61%, dividend $5.14 per share (yield 2.34%). Price averages: 50-day $203.23, 200-day $175.96. The company shows solid cash generation but elevated price-to-book 6.72, implying premium valuation versus peers.
JNJ stock: technicals and intraday trading setup
Technicals are mixed: RSI 49.51 and ADX 24.81 indicate a neutral trend with tightening volatility (ATR 3.22). Day range is $214.15–$218.86, year high $219.73. Short-term traders should watch a break above $219.73 for momentum or a drop under $214.15 for increased selling pressure. On-balance volume shows steady accumulation but MFI at 12.98 flags intraday oversold readings.
JNJ stock: Meyka AI grade and model forecasts
Meyka AI rates JNJ with a score out of 100: 74.48 (Grade B+) — BUY. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, analyst consensus and forecasts. Meyka AI’s forecast model projects short-term targets of $216.09 (1 month) and $206.13 (3 months), and a 12-month projection of $170.80. Compared with the current price $218.55, the 1-month model implies downside -1.12%, 3-month -5.70%, and 12-month -21.86%. Forecasts are model-based projections and not guarantees.
JNJ stock: analyst posture, price targets and sector context
Sell-side sentiment is skewed toward Buy (19 Buys). Recent independent ratings show an A- company rating (15 Jan 2026) and mixed metric scores: strong ROE/ROA but weaker debt scores. In the Healthcare sector and Drug Manufacturers industry, JNJ’s MedTech exposure adds sensitivity to procedure volume cycles. Use analyst counts and sector trends to frame any post-earnings move; expect amplified moves if guidance deviates from consensus.
Final Thoughts
Key takeaways before Johnson & Johnson’s Q4 report: JNJ stock sits at $218.55 with headline metrics P/E 21.19 and EPS 10.36—valuation reflects steady cash flow and a long dividend record. Our earnings spotlight flags margins and guidance as the main drivers for Jan 21. Meyka AI’s forecast model projects $216.09 in one month and $170.80 at 12 months, implying a near-term downside of -1.12% and longer-term downside of -21.86% versus the current price. Analysts overall favor BUY on counts (19 buys) but premium valuation and potential margin pressure create downside risk if revenue or guidance disappoint. Traders should size positions for event volatility and watch intraday levels $219.73 and $214.15 for trade signals. These views use company data, sector context and Meyka AI’s models; forecasts are not guarantees and not investment advice.
FAQs
When does Johnson & Johnson report Q4 earnings?
Johnson & Johnson will report Q4 results on 21 Jan 2026. JNJ stock traders should watch revenue, margins and guidance in the pre-market release for immediate price reactions.
What is the current valuation and yield for JNJ stock?
JNJ stock trades at $218.55 with a trailing P/E 21.19 and dividend $5.14 (yield 2.34%). Price-to-book is elevated at 6.72, reflecting a premium valuation.
What short-term price targets does Meyka AI show for JNJ stock?
Meyka AI’s model projects $216.09 (1 month) and $206.13 (3 months). These forecasts are model-based projections and are not guarantees of future price performance.
How does analyst sentiment shape JNJ stock expectations?
Sell-side sentiment is tilted to Buy with 19 Buys, 7 Holds, 1 Sell. That mix supports positive post-earnings reaction if guidance is strong, but valuation and margin misses could flip momentum quickly.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
